IBDEI3GX ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,58331,2)
 ;;=^5004465
 ;;^UTILITY(U,$J,358.3,58332,0)
 ;;=H35.32^^272^2906^28
 ;;^UTILITY(U,$J,358.3,58332,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,58332,1,3,0)
 ;;=3^Exudative Age-Related Macular Degeneration
 ;;^UTILITY(U,$J,358.3,58332,1,4,0)
 ;;=4^H35.32
 ;;^UTILITY(U,$J,358.3,58332,2)
 ;;=^5005648
 ;;^UTILITY(U,$J,358.3,58333,0)
 ;;=H35.023^^272^2906^29
 ;;^UTILITY(U,$J,358.3,58333,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,58333,1,3,0)
 ;;=3^Exudative Retinopathy,Bilateral
 ;;^UTILITY(U,$J,358.3,58333,1,4,0)
 ;;=4^H35.023
 ;;^UTILITY(U,$J,358.3,58333,2)
 ;;=^5005588
 ;;^UTILITY(U,$J,358.3,58334,0)
 ;;=H35.022^^272^2906^30
 ;;^UTILITY(U,$J,358.3,58334,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,58334,1,3,0)
 ;;=3^Exudative Retinopathy,Left Eye
 ;;^UTILITY(U,$J,358.3,58334,1,4,0)
 ;;=4^H35.022
 ;;^UTILITY(U,$J,358.3,58334,2)
 ;;=^5005587
 ;;^UTILITY(U,$J,358.3,58335,0)
 ;;=H35.021^^272^2906^31
 ;;^UTILITY(U,$J,358.3,58335,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,58335,1,3,0)
 ;;=3^Exudative Retinopathy,Right Eye
 ;;^UTILITY(U,$J,358.3,58335,1,4,0)
 ;;=4^H35.021
 ;;^UTILITY(U,$J,358.3,58335,2)
 ;;=^5005586
 ;;^UTILITY(U,$J,358.3,58336,0)
 ;;=H40.013^^272^2906^32
 ;;^UTILITY(U,$J,358.3,58336,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,58336,1,3,0)
 ;;=3^Glaucoma Suspect,Open Angle w/ Borderline Findings,Low Risk,Bilateral
 ;;^UTILITY(U,$J,358.3,58336,1,4,0)
 ;;=4^H40.013
 ;;^UTILITY(U,$J,358.3,58336,2)
 ;;=^5005726
 ;;^UTILITY(U,$J,358.3,58337,0)
 ;;=H40.012^^272^2906^33
 ;;^UTILITY(U,$J,358.3,58337,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,58337,1,3,0)
 ;;=3^Glaucoma Suspect,Open Angle w/ Borderline Findings,Low Risk,Left Eye
 ;;^UTILITY(U,$J,358.3,58337,1,4,0)
 ;;=4^H40.012
 ;;^UTILITY(U,$J,358.3,58337,2)
 ;;=^5005725
 ;;^UTILITY(U,$J,358.3,58338,0)
 ;;=H40.011^^272^2906^34
 ;;^UTILITY(U,$J,358.3,58338,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,58338,1,3,0)
 ;;=3^Glaucoma Suspect,Open Angle w/ Borderline Findings,Low Risk,Right Eye
 ;;^UTILITY(U,$J,358.3,58338,1,4,0)
 ;;=4^H40.011
 ;;^UTILITY(U,$J,358.3,58338,2)
 ;;=^5005724
 ;;^UTILITY(U,$J,358.3,58339,0)
 ;;=H52.03^^272^2906^41
 ;;^UTILITY(U,$J,358.3,58339,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,58339,1,3,0)
 ;;=3^Hypermetropia,Bilateral
 ;;^UTILITY(U,$J,358.3,58339,1,4,0)
 ;;=4^H52.03
 ;;^UTILITY(U,$J,358.3,58339,2)
 ;;=^5006262
 ;;^UTILITY(U,$J,358.3,58340,0)
 ;;=H52.02^^272^2906^42
 ;;^UTILITY(U,$J,358.3,58340,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,58340,1,3,0)
 ;;=3^Hypermetropia,Left Eye
 ;;^UTILITY(U,$J,358.3,58340,1,4,0)
 ;;=4^H52.02
 ;;^UTILITY(U,$J,358.3,58340,2)
 ;;=^5006261
 ;;^UTILITY(U,$J,358.3,58341,0)
 ;;=H52.01^^272^2906^43
 ;;^UTILITY(U,$J,358.3,58341,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,58341,1,3,0)
 ;;=3^Hypermetropia,Right Eye
 ;;^UTILITY(U,$J,358.3,58341,1,4,0)
 ;;=4^H52.01
 ;;^UTILITY(U,$J,358.3,58341,2)
 ;;=^5006260
 ;;^UTILITY(U,$J,358.3,58342,0)
 ;;=H59.41^^272^2906^44
 ;;^UTILITY(U,$J,358.3,58342,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,58342,1,3,0)
 ;;=3^Inflammation of Postprocedural Bleb,Stage 1
 ;;^UTILITY(U,$J,358.3,58342,1,4,0)
 ;;=4^H59.41
 ;;^UTILITY(U,$J,358.3,58342,2)
 ;;=^5006426
 ;;^UTILITY(U,$J,358.3,58343,0)
 ;;=H59.42^^272^2906^45
 ;;^UTILITY(U,$J,358.3,58343,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,58343,1,3,0)
 ;;=3^Inflammation of Postprocedural Bleb,Stage 2
 ;;^UTILITY(U,$J,358.3,58343,1,4,0)
 ;;=4^H59.42
 ;;^UTILITY(U,$J,358.3,58343,2)
 ;;=^5006427
 ;;^UTILITY(U,$J,358.3,58344,0)
 ;;=H59.43^^272^2906^46
 ;;^UTILITY(U,$J,358.3,58344,1,0)
 ;;=^358.31IA^4^2
